Kura Oncology, Inc.
KURA
$7.54
-$0.11-1.44%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 15.29M | 14.11M | 53.88M | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 15.29M | 14.11M | 53.88M | -- | -- |
| Cost of Revenue | 62.79M | 55.97M | 155.35M | -- | 39.73M |
| Gross Profit | -47.50M | -41.87M | -101.46M | -- | -39.73M |
| SG&A Expenses | 25.17M | 22.84M | 24.07M | 18.18M | 16.68M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 87.95M | 78.81M | 76.34M | 59.88M | 56.40M |
| Operating Income | -72.67M | -64.70M | -22.46M | -59.88M | -56.40M |
| Income Before Tax | -66.12M | -57.20M | -17.20M | -54.40M | -50.84M |
| Income Tax Expenses | -- | 226.00K | 2.02M | -- | -- |
| Earnings from Continuing Operations | -66.12M | -57.43M | -19.22M | -54.40M | -50.84M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -66.12M | -57.43M | -19.22M | -54.40M | -50.84M |
| EBIT | -72.67M | -64.70M | -22.46M | -59.88M | -56.40M |
| EBITDA | -72.44M | -64.46M | -22.25M | -59.68M | -56.20M |
| EPS Basic | -0.75 | -0.66 | -0.22 | -0.63 | -0.59 |
| Normalized Basic EPS | -0.47 | -0.41 | -0.22 | -0.39 | -0.37 |
| EPS Diluted | -0.75 | -0.66 | -0.22 | -0.63 | -0.59 |
| Normalized Diluted EPS | -0.47 | -0.41 | -0.22 | -0.39 | -0.37 |
| Average Basic Shares Outstanding | 87.59M | 87.42M | 87.14M | 86.95M | 86.64M |
| Average Diluted Shares Outstanding | 87.59M | 87.42M | 87.14M | 86.95M | 86.64M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |